Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
SALT LAKE CITY, April 27, 2018 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at two upcoming investor conferences. On May 8, 2018, Mr. Capone will present at the 43rd annual Deutsche Bank Healthcare Conference in Boston at 12:50 p.m. ET. On May 16, 2018, Mr. Capone will present at the Bank of America Healthcare Conference in Las Vegas, Nevada at 6:40 p.m. ET.
The presentations will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
| Media Contact: | Ron Rogers (801) 584-3065 [email protected] | Investor Contact: | Scott Gleason (801) 584-1143 [email protected] |
